远离中概股A股股权的个人主页 - 老虎社区

远离中概股A股股权

远离中概股A股股权

暂无个人介绍

IP属地：江苏

27关注

23粉丝

0主题

0勋章

远离中概股A股股权

06-09

美国总统毫无底线，上任后24小时解决俄乌问题🙋

37次“即将达成”！特朗普不断预告伊朗协议，却一次次落空

远离中概股A股股权

06-04

欧洲也开放，加上肺癌批准，估计这股能冲到100以上了

Iovance公司Amtagvi® (Lifileucel)获澳大利亚批准用于治疗晚期黑色素瘤

远离中概股A股股权

04-14

$伯克希尔B(BRK.B)$ 不能因为价值投资就买它了又一个教训

远离中概股A股股权

04-14

$伯克希尔B(BRK.B)$ 不能因为价值投资就买它了又一个教训

远离中概股A股股权

01-23

$伯克希尔B(BRK.B)$ 价值投资，看着后面猛涨吧

远离中概股A股股权

01-13

也没有见你涨到60

诺和诺德：口服减肥药将进一步扩大GLP-1药物市场

远离中概股A股股权

01-13

$拼多多(PDD)$ 为啥最近跌这么多啊

远离中概股A股股权

01-12

开盘就是咋

@远离中概股A股股权:$诺和诺德(NVO)$ 大家看这周能破60吗？

远离中概股A股股权

01-12

$诺和诺德(NVO)$ 大家看这周能破60吗？

远离中概股A股股权

01-12

$诺和诺德(NVO)$ 好不容易涨下结果遇到大盘不行回调这么多

远离中概股A股股权

01-09

$诺和诺德(NVO)$ 最近发啥疯，涨了好几天了

远离中概股A股股权

01-07

$诺和诺德(NVO)$ 希望这周能冲破60大关[得意] [得意] [得意] [得意] [得意] [得意]

远离中概股A股股权

01-06

$诺和诺德(NVO)$ 没有想到最近这么猛

远离中概股A股股权

2025-12-02

$诺和诺德(NVO)$ 愿赌服输，跌跌

远离中概股A股股权

2025-11-26

$诺和诺德(NVO)$ 为啥涨？

远离中概股A股股权

2025-11-21

$诺和诺德(NVO)$ 这货就是每天都跌

远离中概股A股股权

2025-11-20

我看能成功，神药

诺和诺德将开展高风险阿尔茨海默病研究

远离中概股A股股权

2025-11-18

$诺和诺德(NVO)$ 真是能跌啊，为啥我就买了它[流泪]

远离中概股A股股权

2025-11-17

$诺和诺德(NVO)$ 每天都做空它真能赚不少钱

远离中概股A股股权

2025-11-14

$诺和诺德(NVO)$ 有开始漫长的爹爹了

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3452505216401608","uuid":"3452505216401608","gmtCreate":1492529584078,"gmtModify":1734062313087,"name":"远离中概股A股股权","pinyin":"ylzggaggqyuanlizhonggaiguaguguquan","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","hatId":"ca_profile_frame_DWr5S1","hatName":"LV3 头像框","vip":1,"status":2,"fanSize":23,"headSize":27,"tweetSize":500,"questionSize":0,"limitLevel":900,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.73%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.13%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":1,"location":"江苏","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":14,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":573395599614056,"gmtCreate":1781018798221,"gmtModify":1781021178773,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"美国总统毫无底线，上任后24小时解决俄乌问题🙋","listText":"美国总统毫无底线，上任后24小时解决俄乌问题🙋","text":"美国总统毫无底线，上任后24小时解决俄乌问题🙋","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/573395599614056","repostId":"2642464134","repostType":2,"repost":{"id":"2642464134","kind":"highlight","weMediaInfo":{"introduction":"追踪全球财经热点，精选影响您财富的资讯，投资理财必备神器！","home_visible":1,"media_name":"华尔街见闻","id":"1084101182","head_image":"https://static.tigerbbs.com/66809d1f5c2e43e2bdf15820c6d6897e"},"pubTimestamp":1781003101,"share":"https://www.laohu8.com/m/news/2642464134?lang=zh_CN&edition=full","pubTime":"2026-06-09 19:05","market":"hk","language":"zh","title":"37次“即将达成”！特朗普不断预告伊朗协议，却一次次落空","url":"https://stock-news.laohu8.com/highlight/detail?id=2642464134","media":"华尔街见闻","summary":"37次“即将达成”协议，0次落地。特朗普6月9日再称美伊谈判‘两到三天内’敲定，但自3月以来其乐观表态已导致市场敏感性下降。分析人士指出，此类口头信号的可信度已严重受损。大宗商品投资者在评估“即将达成”类声明时，宜维持较高的预期折扣系数。","content":"<html><head></head><body><blockquote><p>37次“即将达成”协议，0次落地。特朗普6月9日再称美伊谈判‘两到三天内’敲定，但自3月以来其乐观表态已导致市场敏感性下降。分析人士指出，此类口头信号的可信度已严重受损。大宗商品投资者在评估“即将达成”类声明时，宜维持较高的预期折扣系数。</p></blockquote><p style=\"text-align: left;\">当地时间6月9日，特朗普再度表示，美伊谈判已进入“最后关头”。</p><p style=\"text-align: left;\">据新华社，特朗普9日在纽约肯尼迪国际机场接受记者采访时说，“我们正处在最后关头，将达成一份非常、非常棒的协议”。<strong>当被问及谈判还需耗时多久，特朗普回答：“两到三天。”</strong></p><p style=\"text-align: left;\">然而，据媒体统计，过去两个多月间，<strong>特朗普已至少37次公开释放类似乐观信号</strong>。自4月7日宣布停火以来，其措辞从“非常接近协议”到“伊朗愿给一切”不断升级，<strong>但始终未见实质性成果落地</strong>。</p><p style=\"text-align: left;\">分析人士认为，<strong>此类反复出现的表态模式正削弱其市场参考价值</strong>。无论出于稳定金融市场考量，还是制造舆论压力推动谈判，缺乏具体进展支撑的口头信号，已引发投资者系统性降低敏感度。</p><h2 id=\"id_2290830803\" style=\"text-align: left;\">37次“即将达成”：一份未能落地的表态时间线</h2><p style=\"text-align: left;\">据CNN统计，自3月23日以来，<strong>特朗普已至少37次公开表示美伊协议“即将达成”或伊朗“迫切希望谈判”。</strong></p><p style=\"text-align: left;\">时间线显示，这一模式始于停火之前。3月23日，特朗普称双方已就“几乎所有要点”达成共识，但伊朗随即否认存在任何谈判。此后其措辞逐步升级：3月25日称伊朗“非常想达成协议”，3月26日称伊朗“在乞求达成协议”，3月29日则称“我确实预见到伊朗协议”。</p><p style=\"text-align: left;\">4月7日宣布停火后，<strong>特朗普将原定两周的谈判窗口描述为协议“最终确定”所需时间，但两周后协议并未落地</strong>。此后，他在4月15日、17日前后多次重申协议“非常接近”，4月30日又称伊朗“渴望达成协议”。</p><p style=\"text-align: left;\">进入5月，表态节奏未见放缓。5月18日，他以中东国家请求为由，将军事打击推迟“两三天”，理由是各方“认为非常接近达成协议”。5月23日，他表示协议“基本谈完，等待最终确认”，并称将“很快”宣布。5月28日，他在访谈中再次表示“接近一项非常好的协议”。</p><h2 id=\"id_3129771225\" style=\"text-align: left;\">信号失灵：反复口头表态侵蚀市场参考价值</h2><p style=\"text-align: left;\">特朗普本人在5月18日罕见承认此前预测落空：“我们曾有过几段时期，以为相当接近达成协议，但最终没有成功。”尽管他补充称“这次有些不同”，但后续走势再度证明情况并无实质变化。</p><p style=\"text-align: left;\">CNN分析指出，<strong>特朗普持续发出此类信号，或源于判断失误，或为稳定金融市场而有意为之，亦或试图通过反复表态将其“自我实现”。但无论动机如何，这一模式已严重侵蚀相关声明的市场信号价值。</strong></p><p style=\"text-align: left;\">对依赖地缘风险溢价定价的大宗商品及能源市场而言，单一政治表态已难以构成可靠的交易依据。在协议实质性落地之前，市场有充分理由对“即将达成”类口头声明维持较高的预期折扣。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>37次“即将达成”！特朗普不断预告伊朗协议，却一次次落空</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n37次“即将达成”！特朗普不断预告伊朗协议，却一次次落空\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1084101182\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/66809d1f5c2e43e2bdf15820c6d6897e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">华尔街见闻 </p>\n<p class=\"h-time\">2026-06-09 19:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><blockquote><p>37次“即将达成”协议，0次落地。特朗普6月9日再称美伊谈判‘两到三天内’敲定，但自3月以来其乐观表态已导致市场敏感性下降。分析人士指出，此类口头信号的可信度已严重受损。大宗商品投资者在评估“即将达成”类声明时，宜维持较高的预期折扣系数。</p></blockquote><p style=\"text-align: left;\">当地时间6月9日，特朗普再度表示，美伊谈判已进入“最后关头”。</p><p style=\"text-align: left;\">据新华社，特朗普9日在纽约肯尼迪国际机场接受记者采访时说，“我们正处在最后关头，将达成一份非常、非常棒的协议”。<strong>当被问及谈判还需耗时多久，特朗普回答：“两到三天。”</strong></p><p style=\"text-align: left;\">然而，据媒体统计，过去两个多月间，<strong>特朗普已至少37次公开释放类似乐观信号</strong>。自4月7日宣布停火以来，其措辞从“非常接近协议”到“伊朗愿给一切”不断升级，<strong>但始终未见实质性成果落地</strong>。</p><p style=\"text-align: left;\">分析人士认为，<strong>此类反复出现的表态模式正削弱其市场参考价值</strong>。无论出于稳定金融市场考量，还是制造舆论压力推动谈判，缺乏具体进展支撑的口头信号，已引发投资者系统性降低敏感度。</p><h2 id=\"id_2290830803\" style=\"text-align: left;\">37次“即将达成”：一份未能落地的表态时间线</h2><p style=\"text-align: left;\">据CNN统计，自3月23日以来，<strong>特朗普已至少37次公开表示美伊协议“即将达成”或伊朗“迫切希望谈判”。</strong></p><p style=\"text-align: left;\">时间线显示，这一模式始于停火之前。3月23日，特朗普称双方已就“几乎所有要点”达成共识，但伊朗随即否认存在任何谈判。此后其措辞逐步升级：3月25日称伊朗“非常想达成协议”，3月26日称伊朗“在乞求达成协议”，3月29日则称“我确实预见到伊朗协议”。</p><p style=\"text-align: left;\">4月7日宣布停火后，<strong>特朗普将原定两周的谈判窗口描述为协议“最终确定”所需时间，但两周后协议并未落地</strong>。此后，他在4月15日、17日前后多次重申协议“非常接近”，4月30日又称伊朗“渴望达成协议”。</p><p style=\"text-align: left;\">进入5月，表态节奏未见放缓。5月18日，他以中东国家请求为由，将军事打击推迟“两三天”，理由是各方“认为非常接近达成协议”。5月23日，他表示协议“基本谈完，等待最终确认”，并称将“很快”宣布。5月28日，他在访谈中再次表示“接近一项非常好的协议”。</p><h2 id=\"id_3129771225\" style=\"text-align: left;\">信号失灵：反复口头表态侵蚀市场参考价值</h2><p style=\"text-align: left;\">特朗普本人在5月18日罕见承认此前预测落空：“我们曾有过几段时期，以为相当接近达成协议，但最终没有成功。”尽管他补充称“这次有些不同”，但后续走势再度证明情况并无实质变化。</p><p style=\"text-align: left;\">CNN分析指出，<strong>特朗普持续发出此类信号，或源于判断失误，或为稳定金融市场而有意为之，亦或试图通过反复表态将其“自我实现”。但无论动机如何，这一模式已严重侵蚀相关声明的市场信号价值。</strong></p><p style=\"text-align: left;\">对依赖地缘风险溢价定价的大宗商品及能源市场而言，单一政治表态已难以构成可靠的交易依据。在协议实质性落地之前，市场有充分理由对“即将达成”类口头声明维持较高的预期折扣。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/627bc890436e46f74a0fe8143398a725","relate_stocks":{},"source_url":"https://wallstreetcn.com/articles/3774230","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2642464134","content_text":"37次“即将达成”协议，0次落地。特朗普6月9日再称美伊谈判‘两到三天内’敲定，但自3月以来其乐观表态已导致市场敏感性下降。分析人士指出，此类口头信号的可信度已严重受损。大宗商品投资者在评估“即将达成”类声明时，宜维持较高的预期折扣系数。当地时间6月9日，特朗普再度表示，美伊谈判已进入“最后关头”。据新华社，特朗普9日在纽约肯尼迪国际机场接受记者采访时说，“我们正处在最后关头，将达成一份非常、非常棒的协议”。当被问及谈判还需耗时多久，特朗普回答：“两到三天。”然而，据媒体统计，过去两个多月间，特朗普已至少37次公开释放类似乐观信号。自4月7日宣布停火以来，其措辞从“非常接近协议”到“伊朗愿给一切”不断升级，但始终未见实质性成果落地。分析人士认为，此类反复出现的表态模式正削弱其市场参考价值。无论出于稳定金融市场考量，还是制造舆论压力推动谈判，缺乏具体进展支撑的口头信号，已引发投资者系统性降低敏感度。37次“即将达成”：一份未能落地的表态时间线据CNN统计，自3月23日以来，特朗普已至少37次公开表示美伊协议“即将达成”或伊朗“迫切希望谈判”。时间线显示，这一模式始于停火之前。3月23日，特朗普称双方已就“几乎所有要点”达成共识，但伊朗随即否认存在任何谈判。此后其措辞逐步升级：3月25日称伊朗“非常想达成协议”，3月26日称伊朗“在乞求达成协议”，3月29日则称“我确实预见到伊朗协议”。4月7日宣布停火后，特朗普将原定两周的谈判窗口描述为协议“最终确定”所需时间，但两周后协议并未落地。此后，他在4月15日、17日前后多次重申协议“非常接近”，4月30日又称伊朗“渴望达成协议”。进入5月，表态节奏未见放缓。5月18日，他以中东国家请求为由，将军事打击推迟“两三天”，理由是各方“认为非常接近达成协议”。5月23日，他表示协议“基本谈完，等待最终确认”，并称将“很快”宣布。5月28日，他在访谈中再次表示“接近一项非常好的协议”。信号失灵：反复口头表态侵蚀市场参考价值特朗普本人在5月18日罕见承认此前预测落空：“我们曾有过几段时期，以为相当接近达成协议，但最终没有成功。”尽管他补充称“这次有些不同”，但后续走势再度证明情况并无实质变化。CNN分析指出，特朗普持续发出此类信号，或源于判断失误，或为稳定金融市场而有意为之，亦或试图通过反复表态将其“自我实现”。但无论动机如何，这一模式已严重侵蚀相关声明的市场信号价值。对依赖地缘风险溢价定价的大宗商品及能源市场而言，单一政治表态已难以构成可靠的交易依据。在协议实质性落地之前，市场有充分理由对“即将达成”类口头声明维持较高的预期折扣。","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":107,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":571638367285488,"gmtCreate":1780584328648,"gmtModify":1780585431150,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"欧洲也开放，加上肺癌批准，估计这股能冲到100以上了","listText":"欧洲也开放，加上肺癌批准，估计这股能冲到100以上了","text":"欧洲也开放，加上肺癌批准，估计这股能冲到100以上了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/571638367285488","repostId":"1126068070","repostType":2,"repost":{"id":"1126068070","kind":"news","weMediaInfo":{"introduction":"全球快讯第一时间播报","home_visible":1,"media_name":"美股速递","id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"pubTimestamp":1780517115,"share":"https://www.laohu8.com/m/news/1126068070?lang=zh_CN&edition=full","pubTime":"2026-06-04 04:05","market":"us","language":"zh","title":"Iovance公司Amtagvi® (Lifileucel)获澳大利亚批准用于治疗晚期黑色素瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1126068070","media":"美股速递","summary":"Iovance Biotherapeutics公司旗下产品Amtagvi® (Lifileucel)已获得澳大利亚监管机构的批准，用于治疗晚期黑色素瘤。这一进展标志着该细胞疗法在拓展全球市场准入方面迈出了关键一步，为当地晚期黑色素瘤患者提供了一种新的治疗选择。","content":"<p>Iovance Biotherapeutics公司旗下产品Amtagvi® (Lifileucel)已获得澳大利亚监管机构的批准，用于治疗晚期黑色素瘤。这一进展标志着该细胞疗法在拓展全球市场准入方面迈出了关键一步，为当地晚期黑色素瘤患者提供了一种新的治疗选择。</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Iovance公司Amtagvi® (Lifileucel)获澳大利亚批准用于治疗晚期黑色素瘤</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIovance公司Amtagvi® (Lifileucel)获澳大利亚批准用于治疗晚期黑色素瘤\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1004306016\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">美股速递 </p>\n<p class=\"h-time\">2026-06-04 04:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Iovance Biotherapeutics公司旗下产品Amtagvi® (Lifileucel)已获得澳大利亚监管机构的批准，用于治疗晚期黑色素瘤。这一进展标志着该细胞疗法在拓展全球市场准入方面迈出了关键一步，为当地晚期黑色素瘤患者提供了一种新的治疗选择。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IOVA":"Iovance Biotherapeutics, Inc.","BK4139":"生物科技"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126068070","content_text":"Iovance Biotherapeutics公司旗下产品Amtagvi® (Lifileucel)已获得澳大利亚监管机构的批准，用于治疗晚期黑色素瘤。这一进展标志着该细胞疗法在拓展全球市场准入方面迈出了关键一步，为当地晚期黑色素瘤患者提供了一种新的治疗选择。","news_type":1,"symbols_score_info":{"IOVA":1}},"isVote":1,"tweetType":1,"viewCount":299,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3537417120281286","authorId":"3537417120281286","name":"好东西要一直拿着","avatar":"https://static.tigerbbs.com/ed03e24159cdfb1a1cc9e0eb75d70106","crmLevel":7,"crmLevelSwitch":0,"authorIdStr":"3537417120281286","idStr":"3537417120281286"},"content":"肺癌早着呢，批准试验而已。","text":"肺癌早着呢，批准试验而已。","html":"肺癌早着呢，批准试验而已。"},{"author":{"id":"3537417120281286","authorId":"3537417120281286","name":"好东西要一直拿着","avatar":"https://static.tigerbbs.com/ed03e24159cdfb1a1cc9e0eb75d70106","crmLevel":7,"crmLevelSwitch":0,"authorIdStr":"3537417120281286","idStr":"3537417120281286"},"content":"肺癌中期数据还没出，早着呢","text":"肺癌中期数据还没出，早着呢","html":"肺癌中期数据还没出，早着呢"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":553545896220648,"gmtCreate":1776177679604,"gmtModify":1776177681374,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/BRK.B\">$伯克希尔B(BRK.B)$&nbsp;</a><v-v data-views=\"0\"></v-v> 不能因为价值投资就买它了 又一个教训","listText":"<a href=\"https://laohu8.com/S/BRK.B\">$伯克希尔B(BRK.B)$&nbsp;</a><v-v data-views=\"0\"></v-v> 不能因为价值投资就买它了 又一个教训","text":"$伯克希尔B(BRK.B)$ 不能因为价值投资就买它了 又一个教训","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/553545896220648","isVote":1,"tweetType":1,"viewCount":1025,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":553546037388680,"gmtCreate":1776177647350,"gmtModify":1776177649497,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/BRK.B\">$伯克希尔B(BRK.B)$&nbsp;</a> 不能因为价值投资就买它了 又一个教训","listText":"<a href=\"https://laohu8.com/S/BRK.B\">$伯克希尔B(BRK.B)$&nbsp;</a> 不能因为价值投资就买它了 又一个教训","text":"$伯克希尔B(BRK.B)$ 不能因为价值投资就买它了 又一个教训","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/553546037388680","isVote":1,"tweetType":1,"viewCount":1177,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":524972746403840,"gmtCreate":1769172010585,"gmtModify":1769172012266,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/BRK.B\">$伯克希尔B(BRK.B)$&nbsp;</a><v-v data-views=\"1\"></v-v> 价值投资，看着后面猛涨吧","listText":"<a href=\"https://laohu8.com/S/BRK.B\">$伯克希尔B(BRK.B)$&nbsp;</a><v-v data-views=\"1\"></v-v> 价值投资，看着后面猛涨吧","text":"$伯克希尔B(BRK.B)$ 价值投资，看着后面猛涨吧","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/524972746403840","isVote":1,"tweetType":1,"viewCount":2173,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":521299592986984,"gmtCreate":1768310407891,"gmtModify":1768310411350,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"也没有见你涨到60","listText":"也没有见你涨到60","text":"也没有见你涨到60","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/521299592986984","repostId":"2603579529","repostType":2,"repost":{"id":"2603579529","kind":"news","pubTimestamp":1768268932,"share":"https://www.laohu8.com/m/news/2603579529?lang=zh_CN&edition=full","pubTime":"2026-01-13 09:48","market":"us","language":"zh","title":"诺和诺德：口服减肥药将进一步扩大GLP-1药物市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2603579529","media":"格隆汇","summary":"格隆汇1月13日｜诺和诺德首席执行官Mike Doustdar表示，减肥针剂Wegovy的口服版本，将令更多患者愿意使用相关药物，有助开拓尚未使用GLP-1药物的庞大患者群，进一步扩大相关市场。他表示，目前诺和诺德与礼来在美国合共仅向约1000万至1500万名患者销售GLP-1药物，但全美肥胖人口估计约1.1亿人，市场潜力庞大。","content":"<html><body><article><p>格隆汇1月13日｜<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>首席执行官Mike Doustdar表示，减肥针剂Wegovy的口服版本，将令更多患者愿意使用相关药物，有助开拓尚未使用GLP-1药物的庞大患者群，进一步扩大相关市场。他表示，目前诺和诺德与<a href=\"https://laohu8.com/S/LLY\">礼来</a>在美国合共仅向约1000万至1500万名患者销售GLP-1药物，但全美肥胖人口估计约1.1亿人，市场潜力庞大。</p></article></body></html>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>诺和诺德：口服减肥药将进一步扩大GLP-1药物市场</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n诺和诺德：口服减肥药将进一步扩大GLP-1药物市场\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-13 09:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113105654a713ba1a&s=b><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>格隆汇1月13日｜诺和诺德首席执行官Mike Doustdar表示，减肥针剂Wegovy的口服版本，将令更多患者愿意使用相关药物，有助开拓尚未使用GLP-1药物的庞大患者群，进一步扩大相关市场。他表示，目前诺和诺德与礼来在美国合共仅向约1000万至1500万名患者销售GLP-1药物，但全美肥胖人口估计约1.1亿人，市场潜力庞大。</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113105654a713ba1a&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4532":"文艺复兴科技持仓","BK4599":"减肥药","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4144":"石油与天然气的储存和运输","BK4007":"制药","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4590":"PTP","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","NVO":"诺和诺德"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113105654a713ba1a&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2603579529","content_text":"格隆汇1月13日｜诺和诺德首席执行官Mike Doustdar表示，减肥针剂Wegovy的口服版本，将令更多患者愿意使用相关药物，有助开拓尚未使用GLP-1药物的庞大患者群，进一步扩大相关市场。他表示，目前诺和诺德与礼来在美国合共仅向约1000万至1500万名患者销售GLP-1药物，但全美肥胖人口估计约1.1亿人，市场潜力庞大。","news_type":1,"symbols_score_info":{"NVO":1.95}},"isVote":1,"tweetType":1,"viewCount":1778,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":521302748737912,"gmtCreate":1768306035055,"gmtModify":1768306038832,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/PDD\">$拼多多(PDD)$&nbsp;</a> 为啥最近跌这么多啊","listText":"<a href=\"https://laohu8.com/S/PDD\">$拼多多(PDD)$&nbsp;</a> 为啥最近跌这么多啊","text":"$拼多多(PDD)$ 为啥最近跌这么多啊","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/521302748737912","isVote":1,"tweetType":1,"viewCount":1800,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":521010001940528,"gmtCreate":1768228406033,"gmtModify":1768228408280,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"开盘就是咋","listText":"开盘就是咋","text":"开盘就是咋","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/521010001940528","repostId":"520940309562576","repostType":1,"repost":{"id":520940309562576,"gmtCreate":1768203949000,"gmtModify":1768203951933,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 大家看这周能破60吗？","listText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 大家看这周能破60吗？","text":"$诺和诺德(NVO)$ 大家看这周能破60吗？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/520940309562576","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1169,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":520940309562576,"gmtCreate":1768203949000,"gmtModify":1768203951933,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 大家看这周能破60吗？","listText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 大家看这周能破60吗？","text":"$诺和诺德(NVO)$ 大家看这周能破60吗？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":1,"link":"https://laohu8.com/post/520940309562576","isVote":1,"tweetType":1,"viewCount":2972,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":520838985995656,"gmtCreate":1768179217808,"gmtModify":1768179221204,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 好不容易涨下 结果遇到大盘不行 回调这么多","listText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 好不容易涨下 结果遇到大盘不行 回调这么多","text":"$诺和诺德(NVO)$ 好不容易涨下 结果遇到大盘不行 回调这么多","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/520838985995656","isVote":1,"tweetType":1,"viewCount":1815,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":519926014019048,"gmtCreate":1767956395017,"gmtModify":1767956398262,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 最近发啥疯，涨了好几天了","listText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 最近发啥疯，涨了好几天了","text":"$诺和诺德(NVO)$ 最近发啥疯，涨了好几天了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/519926014019048","isVote":1,"tweetType":1,"viewCount":2066,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":519241995219776,"gmtCreate":1767797363166,"gmtModify":1767797365083,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a><v-v data-views=\"1\"></v-v> 希望这周能冲破60大关[得意]&nbsp; [得意]&nbsp; [得意]&nbsp; [得意]&nbsp; [得意]&nbsp; [得意]&nbsp;&nbsp;","listText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a><v-v data-views=\"1\"></v-v> 希望这周能冲破60大关[得意]&nbsp; [得意]&nbsp; [得意]&nbsp; [得意]&nbsp; [得意]&nbsp; [得意]&nbsp;&nbsp;","text":"$诺和诺德(NVO)$ 希望这周能冲破60大关[得意] [得意] [得意] [得意] [得意] [得意]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/519241995219776","isVote":1,"tweetType":1,"viewCount":2841,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3577663334956222","authorId":"3577663334956222","name":"Jeffchung","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":6,"crmLevelSwitch":0,"authorIdStr":"3577663334956222","idStr":"3577663334956222"},"content":"成本80[流泪] 再等一年看看","text":"成本80[流泪] 再等一年看看","html":"成本80[流泪] 再等一年看看"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":518863430635680,"gmtCreate":1767711565330,"gmtModify":1767711567137,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 没有想到最近这么猛","listText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 没有想到最近这么猛","text":"$诺和诺德(NVO)$ 没有想到最近这么猛","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/518863430635680","isVote":1,"tweetType":1,"viewCount":1892,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":506499408704568,"gmtCreate":1764687764974,"gmtModify":1764687766677,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 愿赌服输，跌跌","listText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 愿赌服输，跌跌","text":"$诺和诺德(NVO)$ 愿赌服输，跌跌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/506499408704568","isVote":1,"tweetType":1,"viewCount":1340,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":504341826573160,"gmtCreate":1764158844982,"gmtModify":1764158847064,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 为啥涨？","listText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 为啥涨？","text":"$诺和诺德(NVO)$ 为啥涨？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/504341826573160","isVote":1,"tweetType":1,"viewCount":2728,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":502619646448104,"gmtCreate":1763737950486,"gmtModify":1763737952324,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 这货就是每天都跌","listText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 这货就是每天都跌","text":"$诺和诺德(NVO)$ 这货就是每天都跌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/502619646448104","isVote":1,"tweetType":1,"viewCount":1445,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":502279536255080,"gmtCreate":1763645894865,"gmtModify":1763645897360,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"我看能成功，神药","listText":"我看能成功，神药","text":"我看能成功，神药","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/502279536255080","repostId":"2584136350","repostType":2,"repost":{"id":"2584136350","kind":"news","pubTimestamp":1763639700,"share":"https://www.laohu8.com/m/news/2584136350?lang=zh_CN&edition=full","pubTime":"2025-11-20 19:55","market":"us","language":"zh","title":"诺和诺德将开展高风险阿尔茨海默病研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2584136350","media":"环球市场播报","summary":"诺和诺德公司定于下月初公布的研究数据，将首次为 “重磅 GLP-1 类药物能否延缓阿尔茨海默病进展” 提供最有力的线索。　　诺和诺德将两项试验称为 “幸运彩票”，试验对象为数千名轻度阿尔茨海默病患者，测试药物是其早年推出的糖尿病口服药利拉鲁肽片。阿尔茨海默病的特征是大脑中出现毒性淀粉样蛋白斑块，目前全球患者已达 5000 万人。","content":"<html><body><div>\n<p>　　<span><a href=\"https://laohu8.com/S/NVO\">诺和诺德</a></span><span></span>公司（股票代码：NVO、NOVO-B.CO）定于下月初公布的研究数据，将首次为 “重磅 GLP-1 类药物能否延缓阿尔茨海默病进展” 提供最有力的线索。目前，全球数百万糖尿病患者和减重人群正在使用该类药物。</p>\n<p>　　诺和诺德将两项试验称为 “幸运彩票”，试验对象为数千名轻度阿尔茨海默病患者，测试药物是其早年推出的糖尿病口服药利拉鲁肽片（Rybelsus）。该药物与司美格鲁肽注射液（Ozempic，中文商品名 “诺和泰”）、 Wegovy（中文商品名 “诺和盈”）含有相同的活性成分 —— 司美格鲁肽（semaglutide），试验目标是将患者的认知衰退速度降低至少 20%。</p>\n<p>　　阿尔茨海默病领域专家表示，若试验成功，将催生一种便捷的新型疗法，用于延缓这种 “侵蚀大脑” 的疾病进展。阿尔茨海默病的特征是大脑中出现毒性淀粉样蛋白斑块，目前全球患者已达 5000 万人。</p>\n<p>　　无论试验结果如何，研究人员均有望获得重要线索，为未来研究 “GLP-1 类药物（包括<span><a href=\"https://laohu8.com/S/LLY\">礼来</a></span><span></span>公司的 Zepbound 和 Mounjaro）为何及如何对阿尔茨海默病产生潜在疗效” 奠定基础。</p>\n<p>　　“这项研究确实有可能带来变革性影响。” 阿尔茨海默病协会首席科学官玛丽亚・卡里略表示。</p>\n<p>　　她与其他领域专家向路透社透露，目前尚不清楚以 GLP-1 受体为作用靶点的药物如何影响大脑。</p>\n<p>　　目前支持 GLP-1 类药物用于阿尔茨海默病试验的多数证据，均来自其在 “糖尿病合并肥胖相关痴呆患者” 中的应用数据。</p>\n<p>　　诺和诺德一位发言人指出，该公司于 2021 年启动阿尔茨海默病研究，依据包括两方面：一是动物实验证据，二是对人类研究的分析 —— 后者显示，接受 GLP-1 类药物治疗的糖尿病患者，其痴呆或阿尔茨海默病发病风险更低。此外，一项针对该公司早年推出的 GLP-1 类注射剂利拉鲁肽（liraglutide）的小型研究发现，该药物可减缓轻度阿尔茨海默病患者的脑容量流失速度。</p>\n<p>　　<strong>试验成功或推动诺和诺德股价上涨</strong></p>\n<p>　　专家表示，若利拉鲁肽片能延缓早期阿尔茨海默病患者的认知衰退，其安全性和便捷性将优于 “淀粉样蛋白清除类药物”。不过，利拉鲁肽片的用药要求较高：需空腹服用，且服药后 30 分钟内不得进食、饮水或服用其他口服药物。</p>\n<p>　　华尔街分析师预测，若试验明确成功，诺和诺德股价或最高上涨 10%；若试验失败，股价可能下跌 5%。</p>\n<p>　　诺和诺德计划于 12 月 3 日在圣地亚哥举行的 “阿尔茨海默病临床试验会议” 上公布试验结果，但也可能在此之前提前披露部分数据。</p>\n<p>　　“从市场推广角度看，一款安全的口服药物意义重大。这类药物的（上市）门槛会非常低。” 诺普曼（Knopman）表示。</p>\n<p>　　<strong>GLP-1 类药物对大脑的作用机制尚不明确</strong></p>\n<p>　　约 60% 的痴呆患者为阿尔茨海默病患者，其余患者则患有血管性痴呆（由脑部血流受阻引发）等疾病，且许多患者同时患有多种类型的痴呆。</p>\n<p>　　纽约西奈山医院阿尔茨海默病研究员、该试验项目研究者玛丽・萨诺博士指出，由于试验要求所有参与者需确诊为阿尔茨海默病，因此难以招募同时患有血管性痴呆的患者 —— 这类患者在糖尿病群体中较为常见，但他们的病情通常已进展到不符合试验入组标准的阶段。</p>\n<p>　　<strong>目前在理解 GLP-1 类药物对大脑作用方面存在哪些挑战？</strong></p>\n<p>　　科学家表示，此前研究中 GLP-1 类药物降低痴呆风险的具体机制仍不明确。可能的作用路径包括两种：一是药物直接对大脑产生影响；二是药物通过减重、减轻体内炎症等间接改善身体状态，进而保护大脑。</p>\n<p>　　此外，并非所有 GLP-1 类药物的作用都相同。弗吉尼亚大学内分泌学家希瑟・费里斯博士指出，小鼠实验显示，利拉鲁肽（商品名：Victoza “诺和力”、Saxenda “诺和盈”）进入大脑的难度低于司美格鲁肽。</p>\n<p>　　费里斯预计，诺和诺德的此次研究 “可能会取得阳性结果，但效果有限”。</p>\n<p>　　明尼苏达州罗切斯特市梅奥诊所神经科医生戴维・诺普曼博士表示：“目前完全不清楚大脑中的 GLP-1 靶点与阿尔茨海默病病理之间存在何种关联，这并非一个积极信号。”</p>\n<p>　　目前全球已批准两款通过清除大脑淀粉样蛋白来延缓阿尔茨海默病的药物：礼来公司的 Kisunla，以及卫材（Eisai）与渤健（Biogen）联合研发的 Leqembi（中文商品名 “仑卡奈单抗”）。这两款药物均通过输液或注射给药，临床试验显示其可将疾病进展速度减缓近 30%，但同时存在严重副作用风险，且需定期进行影像学检查。</p>\n<p>　　<strong>试验结果或为未来研究指明方向</strong></p>\n<p>　　阿尔茨海默病药物研发基金会（该机构为包括利拉鲁肽研究在内的多个阿尔茨海默病研究项目提供资金支持）的霍华德・菲利特博士表示，诺和诺德的试验或可揭示 GLP-1 类药物对 “大脑代谢年龄相关变化” 的影响 —— 这类变化发生在淀粉样蛋白斑块形成之前。</p>\n<p>　　他指出，若利拉鲁肽片能将认知衰退速度减缓近 30%，该研究将被视为明确成功。</p>\n<p>　　菲利特补充称，即便未达到这一目标，试验结果也能为未来的试验设计提供指导，包括探索 GLP-1 类药物与现有阿尔茨海默病药物联合使用的可能性。</p>\n<p>　　礼来公司表示，将 “持续密切关注不断发展的科学研究，以更好地理解 GLP-1 类药物在大脑健康中的作用”。目前，礼来正开展一项研究，探索 Kisunla 能否在阿尔茨海默病症状出现前预防疾病发生，该试验预计于 2027 年结束。</p>\n<p>　　卫材与渤健也在针对 Leqembi 开展类似的预防研究。卫材在一份声明中表示，若诺和诺德的试验能证明司美格鲁肽具有显著临床益处，该药物或可成为 Leqembi 等药物的补充治疗选择。</p>\n<div>\n<div><img src=\"\"/></div>\n<div>海量资讯、精准解读，尽在新浪财经APP</div>\n</div>\n<p>责任编辑：郭明煜 </p>\n</div></body></html>","source":"sina","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>诺和诺德将开展高风险阿尔茨海默病研究</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n诺和诺德将开展高风险阿尔茨海默病研究\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-20 19:55 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/usstock/c/2025-11-20/doc-infyafyr2509688.shtml><strong>环球市场播报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>诺和诺德公司（股票代码：NVO、NOVO-B.CO）定于下月初公布的研究数据，将首次为 “重磅 GLP-1 类药物能否延缓阿尔茨海默病进展” 提供最有力的线索。目前，全球数百万糖尿病患者和减重人群正在使用该类药物。\n　　诺和诺德将两项试验称为 “幸运彩票”，试验对象为数千名轻度阿尔茨海默病患者，测试药物是其早年推出的糖尿病口服药利拉鲁肽片（Rybelsus）。该药物与司美格鲁肽注射液（...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2025-11-20/doc-infyafyr2509688.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4599":"减肥药","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4007":"制药","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4588":"碎股","NVO":"诺和诺德","BK4585":"ETF&股票定投概念","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4532":"文艺复兴科技持仓"},"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-11-20/doc-infyafyr2509688.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","article_id":"2584136350","content_text":"诺和诺德公司（股票代码：NVO、NOVO-B.CO）定于下月初公布的研究数据，将首次为 “重磅 GLP-1 类药物能否延缓阿尔茨海默病进展” 提供最有力的线索。目前，全球数百万糖尿病患者和减重人群正在使用该类药物。\n　　诺和诺德将两项试验称为 “幸运彩票”，试验对象为数千名轻度阿尔茨海默病患者，测试药物是其早年推出的糖尿病口服药利拉鲁肽片（Rybelsus）。该药物与司美格鲁肽注射液（Ozempic，中文商品名 “诺和泰”）、 Wegovy（中文商品名 “诺和盈”）含有相同的活性成分 —— 司美格鲁肽（semaglutide），试验目标是将患者的认知衰退速度降低至少 20%。\n　　阿尔茨海默病领域专家表示，若试验成功，将催生一种便捷的新型疗法，用于延缓这种 “侵蚀大脑” 的疾病进展。阿尔茨海默病的特征是大脑中出现毒性淀粉样蛋白斑块，目前全球患者已达 5000 万人。\n　　无论试验结果如何，研究人员均有望获得重要线索，为未来研究 “GLP-1 类药物（包括礼来公司的 Zepbound 和 Mounjaro）为何及如何对阿尔茨海默病产生潜在疗效” 奠定基础。\n　　“这项研究确实有可能带来变革性影响。” 阿尔茨海默病协会首席科学官玛丽亚・卡里略表示。\n　　她与其他领域专家向路透社透露，目前尚不清楚以 GLP-1 受体为作用靶点的药物如何影响大脑。\n　　目前支持 GLP-1 类药物用于阿尔茨海默病试验的多数证据，均来自其在 “糖尿病合并肥胖相关痴呆患者” 中的应用数据。\n　　诺和诺德一位发言人指出，该公司于 2021 年启动阿尔茨海默病研究，依据包括两方面：一是动物实验证据，二是对人类研究的分析 —— 后者显示，接受 GLP-1 类药物治疗的糖尿病患者，其痴呆或阿尔茨海默病发病风险更低。此外，一项针对该公司早年推出的 GLP-1 类注射剂利拉鲁肽（liraglutide）的小型研究发现，该药物可减缓轻度阿尔茨海默病患者的脑容量流失速度。\n　　试验成功或推动诺和诺德股价上涨\n　　专家表示，若利拉鲁肽片能延缓早期阿尔茨海默病患者的认知衰退，其安全性和便捷性将优于 “淀粉样蛋白清除类药物”。不过，利拉鲁肽片的用药要求较高：需空腹服用，且服药后 30 分钟内不得进食、饮水或服用其他口服药物。\n　　华尔街分析师预测，若试验明确成功，诺和诺德股价或最高上涨 10%；若试验失败，股价可能下跌 5%。\n　　诺和诺德计划于 12 月 3 日在圣地亚哥举行的 “阿尔茨海默病临床试验会议” 上公布试验结果，但也可能在此之前提前披露部分数据。\n　　“从市场推广角度看，一款安全的口服药物意义重大。这类药物的（上市）门槛会非常低。” 诺普曼（Knopman）表示。\n　　GLP-1 类药物对大脑的作用机制尚不明确\n　　约 60% 的痴呆患者为阿尔茨海默病患者，其余患者则患有血管性痴呆（由脑部血流受阻引发）等疾病，且许多患者同时患有多种类型的痴呆。\n　　纽约西奈山医院阿尔茨海默病研究员、该试验项目研究者玛丽・萨诺博士指出，由于试验要求所有参与者需确诊为阿尔茨海默病，因此难以招募同时患有血管性痴呆的患者 —— 这类患者在糖尿病群体中较为常见，但他们的病情通常已进展到不符合试验入组标准的阶段。\n　　目前在理解 GLP-1 类药物对大脑作用方面存在哪些挑战？\n　　科学家表示，此前研究中 GLP-1 类药物降低痴呆风险的具体机制仍不明确。可能的作用路径包括两种：一是药物直接对大脑产生影响；二是药物通过减重、减轻体内炎症等间接改善身体状态，进而保护大脑。\n　　此外，并非所有 GLP-1 类药物的作用都相同。弗吉尼亚大学内分泌学家希瑟・费里斯博士指出，小鼠实验显示，利拉鲁肽（商品名：Victoza “诺和力”、Saxenda “诺和盈”）进入大脑的难度低于司美格鲁肽。\n　　费里斯预计，诺和诺德的此次研究 “可能会取得阳性结果，但效果有限”。\n　　明尼苏达州罗切斯特市梅奥诊所神经科医生戴维・诺普曼博士表示：“目前完全不清楚大脑中的 GLP-1 靶点与阿尔茨海默病病理之间存在何种关联，这并非一个积极信号。”\n　　目前全球已批准两款通过清除大脑淀粉样蛋白来延缓阿尔茨海默病的药物：礼来公司的 Kisunla，以及卫材（Eisai）与渤健（Biogen）联合研发的 Leqembi（中文商品名 “仑卡奈单抗”）。这两款药物均通过输液或注射给药，临床试验显示其可将疾病进展速度减缓近 30%，但同时存在严重副作用风险，且需定期进行影像学检查。\n　　试验结果或为未来研究指明方向\n　　阿尔茨海默病药物研发基金会（该机构为包括利拉鲁肽研究在内的多个阿尔茨海默病研究项目提供资金支持）的霍华德・菲利特博士表示，诺和诺德的试验或可揭示 GLP-1 类药物对 “大脑代谢年龄相关变化” 的影响 —— 这类变化发生在淀粉样蛋白斑块形成之前。\n　　他指出，若利拉鲁肽片能将认知衰退速度减缓近 30%，该研究将被视为明确成功。\n　　菲利特补充称，即便未达到这一目标，试验结果也能为未来的试验设计提供指导，包括探索 GLP-1 类药物与现有阿尔茨海默病药物联合使用的可能性。\n　　礼来公司表示，将 “持续密切关注不断发展的科学研究，以更好地理解 GLP-1 类药物在大脑健康中的作用”。目前，礼来正开展一项研究，探索 Kisunla 能否在阿尔茨海默病症状出现前预防疾病发生，该试验预计于 2027 年结束。\n　　卫材与渤健也在针对 Leqembi 开展类似的预防研究。卫材在一份声明中表示，若诺和诺德的试验能证明司美格鲁肽具有显著临床益处，该药物或可成为 Leqembi 等药物的补充治疗选择。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：郭明煜","news_type":1,"symbols_score_info":{"NVO":1.5}},"isVote":1,"tweetType":1,"viewCount":1482,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":501564220715552,"gmtCreate":1763459700158,"gmtModify":1763459702096,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 真是能跌啊，为啥我就买了它[流泪]&nbsp;&nbsp;","listText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 真是能跌啊，为啥我就买了它[流泪]&nbsp;&nbsp;","text":"$诺和诺德(NVO)$ 真是能跌啊，为啥我就买了它[流泪]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/501564220715552","isVote":1,"tweetType":1,"viewCount":1974,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4110747462729630","authorId":"4110747462729630","name":"亏完就走","avatar":"https://static.tigerbbs.com/4239473bbf98759e23c8d47fcde2c29e","crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"4110747462729630","idStr":"4110747462729630"},"content":"等个历史最低位上车😊😊","text":"等个历史最低位上车😊😊","html":"等个历史最低位上车😊😊"},{"author":{"id":"3546249304196282","authorId":"3546249304196282","name":"火火兔爸","avatar":"https://static.tigerbbs.com/1914631c23e50a7645217a36cc9d9598","crmLevel":9,"crmLevelSwitch":1,"authorIdStr":"3546249304196282","idStr":"3546249304196282"},"content":"因为你嫌礼来贵，贪便宜。","text":"因为你嫌礼来贵，贪便宜。","html":"因为你嫌礼来贵，贪便宜。"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":501171437219968,"gmtCreate":1763386284451,"gmtModify":1763386286191,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 每天都做空它真能赚不少钱","listText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 每天都做空它真能赚不少钱","text":"$诺和诺德(NVO)$ 每天都做空它真能赚不少钱","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/501171437219968","isVote":1,"tweetType":1,"viewCount":1348,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":499931420983376,"gmtCreate":1763079074672,"gmtModify":1763079076347,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 有开始漫长的爹爹了","listText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 有开始漫长的爹爹了","text":"$诺和诺德(NVO)$ 有开始漫长的爹爹了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/499931420983376","isVote":1,"tweetType":1,"viewCount":1314,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":435893475786816,"gmtCreate":1747455291707,"gmtModify":1747455293237,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/IOVA\">$Iovance Biotherapeutics, Inc.(IOVA)$&nbsp;</a>&nbsp; Iovance的2025年一季度报告，Amtagvi销售额4300多万美元，Proleukin销售额不到600万左右。而2024年下半年，Amtagvi销售额为9千万美元左右，IL-2卖了4千万美元。这表明在2025年一季度细胞疗法没有明显增长放量，更糟糕的是前瞻性IL-2的销售额居然远远小于2千万美元。不出意外，二季度的成绩大概率会很差。","listText":"<a href=\"https://laohu8.com/S/IOVA\">$Iovance Biotherapeutics, Inc.(IOVA)$&nbsp;</a>&nbsp; Iovance的2025年一季度报告，Amtagvi销售额4300多万美元，Proleukin销售额不到600万左右。而2024年下半年，Amtagvi销售额为9千万美元左右，IL-2卖了4千万美元。这表明在2025年一季度细胞疗法没有明显增长放量，更糟糕的是前瞻性IL-2的销售额居然远远小于2千万美元。不出意外，二季度的成绩大概率会很差。","text":"$Iovance Biotherapeutics, Inc.(IOVA)$ Iovance的2025年一季度报告，Amtagvi销售额4300多万美元，Proleukin销售额不到600万左右。而2024年下半年，Amtagvi销售额为9千万美元左右，IL-2卖了4千万美元。这表明在2025年一季度细胞疗法没有明显增长放量，更糟糕的是前瞻性IL-2的销售额居然远远小于2千万美元。不出意外，二季度的成绩大概率会很差。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/435893475786816","isVote":1,"tweetType":1,"viewCount":6967,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3495872648664068","authorId":"3495872648664068","name":"Washington89","avatar":"https://static.tigerbbs.com/c207e38fa1a9a6a175efc215b6ab4953","crmLevel":9,"crmLevelSwitch":1,"authorIdStr":"3495872648664068","idStr":"3495872648664068"},"content":"IL2销售已经反弹了了，主要Q1分销售存货过多。","text":"IL2销售已经反弹了了，主要Q1分销售存货过多。","html":"IL2销售已经反弹了了，主要Q1分销售存货过多。"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":372259768656200,"gmtCreate":1731923389563,"gmtModify":1732086602998,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/OPT/NVDA 20250117 100.0 PUT\">$NVDA 20250117 100.0 PUT$</a> 不知道今天能否回本呢？求大神指导下，是不是要快点卖出去了，英伟达太猛了","listText":"<a href=\"https://laohu8.com/OPT/NVDA 20250117 100.0 PUT\">$NVDA 20250117 100.0 PUT$</a> 不知道今天能否回本呢？求大神指导下，是不是要快点卖出去了，英伟达太猛了","text":"$NVDA 20250117 100.0 PUT$ 不知道今天能否回本呢？求大神指导下，是不是要快点卖出去了，英伟达太猛了","images":[{"img":"https://static.tigerbbs.com/3c3971e9e925a8adc0904ea5b5996b9c","width":"981","height":"1637"}],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":5,"commentSize":10,"repostSize":0,"link":"https://laohu8.com/post/372259768656200","isVote":1,"tweetType":1,"viewCount":5541,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3536816819213077","authorId":"3536816819213077","name":"买绿不买红","avatar":"https://static.tigerbbs.com/441eb9795d8315131c538c3216d8f9a2","crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"3536816819213077","idStr":"3536816819213077"},"content":"你在英伟达多少买的？ 今天跌的挺多 你开盘应该回本了 马上抛了","text":"你在英伟达多少买的？ 今天跌的挺多 你开盘应该回本了 马上抛了","html":"你在英伟达多少买的？ 今天跌的挺多 你开盘应该回本了 马上抛了"},{"author":{"id":"4088626949262520","authorId":"4088626949262520","name":"Inmoretion","avatar":"https://static.tigerbbs.com/b1c0fdec2b419399e39fd0a7b103ef63","crmLevel":7,"crmLevelSwitch":1,"authorIdStr":"4088626949262520","idStr":"4088626949262520"},"content":"你这实在有点猛啊，跟市场反着干是吧","text":"你这实在有点猛啊，跟市场反着干是吧","html":"你这实在有点猛啊，跟市场反着干是吧"}],"imageCount":1,"langContent":"CN","totalScore":0},{"id":194471,"gmtCreate":1527222216717,"gmtModify":1767750777456,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"今天要跌了","htmlText":"$阿里巴巴(BABA)$ 上不去，加上今天阿里系大跌 估计晚上有好戏了","listText":"$阿里巴巴(BABA)$ 上不去，加上今天阿里系大跌 估计晚上有好戏了","text":"$阿里巴巴(BABA)$ 上不去，加上今天阿里系大跌 估计晚上有好戏了","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":12,"repostSize":0,"link":"https://laohu8.com/post/194471","isVote":1,"tweetType":1,"viewCount":3224,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3483236531603328","authorId":"3483236531603328","name":"Andy2015","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3483236531603328","idStr":"3483236531603328"},"content":"我觉得会涨","text":"我觉得会涨","html":"我觉得会涨"},{"author":{"id":"3450843730457215","authorId":"3450843730457215","name":"忘过去做眼前思未来","avatar":"https://static.tigerbbs.com/bcd4ddf95bdc7bd78bf1327798853041","crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3450843730457215","idStr":"3450843730457215"},"content":"200的call快亏出翔了","text":"200的call快亏出翔了","html":"200的call快亏出翔了"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":182040,"gmtCreate":1524816712993,"gmtModify":1767750777470,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"今天高开低走","htmlText":"$阿里巴巴(BABA)$ 昨天阿里一开始也是让人揪心 希望今天....","listText":"$阿里巴巴(BABA)$ 昨天阿里一开始也是让人揪心 希望今天....","text":"$阿里巴巴(BABA)$ 昨天阿里一开始也是让人揪心 希望今天....","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":12,"repostSize":0,"link":"https://laohu8.com/post/182040","isVote":1,"tweetType":1,"viewCount":1623,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3450866809170934","authorId":"3450866809170934","name":"蚂蚁布丁","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3450866809170934","idStr":"3450866809170934"},"content":"不会高开低走了，除非大环境不好，下周就财报，之前打压那么久，吸筹也够了，我感觉今天能占上180，然后下周借财报回到190-200区间，能不能创新高就看财报了，如果财报创新高，可以大胆做空","text":"不会高开低走了，除非大环境不好，下周就财报，之前打压那么久，吸筹也够了，我感觉今天能占上180，然后下周借财报回到190-200区间，能不能创新高就看财报了，如果财报创新高，可以大胆做空","html":"不会高开低走了，除非大环境不好，下周就财报，之前打压那么久，吸筹也够了，我感觉今天能占上180，然后下周借财报回到190-200区间，能不能创新高就看财报了，如果财报创新高，可以大胆做空"},{"author":{"id":"36936236293264","authorId":"36936236293264","name":"没前途的小伙","avatar":"https://static.laohu8.com/1655876e4110f7aa252300a42f24e314","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"36936236293264","idStr":"36936236293264"},"content":"昨天全仓做空 。。。。","text":"昨天全仓做空 。。。。","html":"昨天全仓做空 。。。。"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":553545896220648,"gmtCreate":1776177679604,"gmtModify":1776177681374,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/BRK.B\">$伯克希尔B(BRK.B)$&nbsp;</a><v-v data-views=\"0\"></v-v> 不能因为价值投资就买它了 又一个教训","listText":"<a href=\"https://laohu8.com/S/BRK.B\">$伯克希尔B(BRK.B)$&nbsp;</a><v-v data-views=\"0\"></v-v> 不能因为价值投资就买它了 又一个教训","text":"$伯克希尔B(BRK.B)$ 不能因为价值投资就买它了 又一个教训","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/553545896220648","isVote":1,"tweetType":1,"viewCount":1025,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":373364597604640,"gmtCreate":1732181414894,"gmtModify":1732181416448,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$&nbsp;</a><v-v data-views=\"1\"></v-v> blackwell不是已经出货1万多块了吗？还跌？[无语]&nbsp;&nbsp;","listText":"<a href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$&nbsp;</a><v-v data-views=\"1\"></v-v> blackwell不是已经出货1万多块了吗？还跌？[无语]&nbsp;&nbsp;","text":"$英伟达(NVDA)$ blackwell不是已经出货1万多块了吗？还跌？[无语]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":6,"repostSize":0,"link":"https://laohu8.com/post/373364597604640","isVote":1,"tweetType":1,"viewCount":5911,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":196388,"gmtCreate":1527755389656,"gmtModify":1767750777418,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"高开低走","htmlText":"$阿里巴巴(BABA)$ 今天又来个高开低走？？","listText":"$阿里巴巴(BABA)$ 今天又来个高开低走？？","text":"$阿里巴巴(BABA)$ 今天又来个高开低走？？","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":10,"repostSize":0,"link":"https://laohu8.com/post/196388","isVote":1,"tweetType":1,"viewCount":3978,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"36503900255130","authorId":"36503900255130","name":"迷雾森林","avatar":"https://static.laohu8.com/27849548a874c044c2774ecb9e654a34","crmLevel":9,"crmLevelSwitch":1,"authorIdStr":"36503900255130","idStr":"36503900255130"},"content":"200为什么总冲不过","text":"200为什么总冲不过","html":"200为什么总冲不过"},{"author":{"id":"167511156172360","authorId":"167511156172360","name":"不动如山","avatar":"https://static.tigerbbs.com/1efc8dc76991faa802ebf53525218d5f","crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"167511156172360","idStr":"167511156172360"},"content":"张近东这王八蛋在卖","text":"张近东这王八蛋在卖","html":"张近东这王八蛋在卖"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":182502,"gmtCreate":1525080496936,"gmtModify":1767750777477,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"今天能上180？？","htmlText":"$阿里巴巴(BABA)$ 大家说说今天能上180吗？","listText":"$阿里巴巴(BABA)$ 大家说说今天能上180吗？","text":"$阿里巴巴(BABA)$ 大家说说今天能上180吗？","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":10,"repostSize":0,"link":"https://laohu8.com/post/182502","isVote":1,"tweetType":1,"viewCount":3463,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"content":"都太乐观了 阿里能上190就很不错了","text":"都太乐观了 阿里能上190就很不错了","html":"都太乐观了 阿里能上190就很不错了"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":238007,"gmtCreate":1533723195740,"gmtModify":1704769709831,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"$纳斯达克(.IXIC)$ 周一是Facebook和苹果拉盘，周二是谷歌和特斯拉拉盘，今天是谁呢？","listText":"$纳斯达克(.IXIC)$ 周一是Facebook和苹果拉盘，周二是谷歌和特斯拉拉盘，今天是谁呢？","text":"$纳斯达克(.IXIC)$ 周一是Facebook和苹果拉盘，周二是谷歌和特斯拉拉盘，今天是谁呢？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":8,"repostSize":0,"link":"https://laohu8.com/post/238007","isVote":1,"tweetType":1,"viewCount":2864,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3464216079351960","authorId":"3464216079351960","name":"小投资者","avatar":"https://static.tigerbbs.com/1c6da3c6303802004150965757ad419f","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3464216079351960","idStr":"3464216079351960"},"content":"今天亚马逊😂😂😂","text":"今天亚马逊😂😂😂","html":"今天亚马逊😂😂😂"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":433006332551432,"gmtCreate":1746747862917,"gmtModify":1746747864543,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/IOVA\">$Iovance Biotherapeutics, Inc.(IOVA)$&nbsp;</a> 完蛋了","listText":"<a href=\"https://laohu8.com/S/IOVA\">$Iovance Biotherapeutics, Inc.(IOVA)$&nbsp;</a> 完蛋了","text":"$Iovance Biotherapeutics, Inc.(IOVA)$ 完蛋了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/433006332551432","isVote":1,"tweetType":1,"viewCount":2725,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3537417120281286","authorId":"3537417120281286","name":"好东西要一直拿着","avatar":"https://static.tigerbbs.com/ed03e24159cdfb1a1cc9e0eb75d70106","crmLevel":7,"crmLevelSwitch":0,"authorIdStr":"3537417120281286","idStr":"3537417120281286"},"content":"你的战绩好像也不是很好啊","text":"你的战绩好像也不是很好啊","html":"你的战绩好像也不是很好啊"}],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}